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ABSTRACT
In previous work, it is suggested that the excessive amount of fatty acids 
transported by FABP5 may facilitate the malignant progression of prostate cancer 
cells through a FABP5-PPARg-VEGF signal transduction axis to increase angiogenesis. 
To further functionally characterise the FABP5-PPARg-VEGF signal transduction 
pathway, we have, in this work, investigated the molecular mechanisms involved 
in its tumorigenicity promoting role in prostate cancer. Suppression of PPARg in 
highly malignant prostate cancer cells produced a significant reduction (up to 53%) 
in their proliferation rate, invasiveness (up to 89%) and anchorage-independent 
growth (up to 94%) in vitro. Knockdown of PPARg gene in PC3-M cells by siRNA 
significantly reduced the average size of tumours formed in nude mice by 99% and 
tumour incidence by 90%, and significantly prolonged the latent period by 3.5 fold. 
Results in this study combined with some previous results suggested that FABP5 
promoted VEGF expression and angiogenesis through PPARg which was activated 
by fatty acids transported by FABP5. Further investigations showed that PPARg 
up-regulated VEGF expression through acting with the PPAR-responsive elements 
in the promoter region of VEGF gene in prostate cancer cells. Although androgen 
can modulate VEGF expression through Sp1/Sp3 binding site on VEGF promoter 
in androgen-dependent prostate cancer cells, this route, disappeared as the cells 
gradually lost their androgen dependency; was replaced by the FABP5-PPARg-VEGF 
signalling pathway. These results suggested that the FABP5-PPARg-VEGF signal 
transduction axis, rather than androgen modulated route, may be a more important 
novel therapeutic target for angiogenesis-suppression treatment of castration 
resistant prostate cancer.
INTRODUCTION
Prostate cancer is a serious health threat to man, 
particularly in the developed countries. High dietary fat 
intake has been shown to have a significant correlation 
with a higher risk of prostate cancer [1] and high levels 
of trans-isomers of oleic and linoleic acids (long chain 
fatty acids) in blood are associated with an increased risk 
of prostate tumours [2]. Fatty acids are not only sources 
of energy in cells, but are also signalling molecules 
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involved in metabolic regulation. Their regulatory effects 
on enzymatic and transcriptional networks can lead to 
regulations in gene expression, cell growth and survival 
pathways and inflammatory responses [3]. Fatty acid 
binding proteins (FABPs) are known as intracellular 
chaperons of lipids. They reversibly bind hydrophobic 
ligands such as saturated and unsaturated fatty acids with 
high affinity and transport them into the cells [4]. FABP5 
is a 15 kDa cytosolic protein which belongs to the FABP 
family [5]. In addition to the skin, FABP5 is detected in 
endothelial cells of placenta, heart, skeletal muscle, small 
intestine, renal medulla and in Clara and goblet cells of 
lung [6]. Apart from prostate cancer, FABP5 has also been 
implicated in malignancies of bladder, pancreas [7, 8], 
breast [9] and glioblastoma [10].
Previous studies demonstrated that FABP5 is 
overexpressed in malignant prostate and breast cell lines 
compared to their benign counterparts and the increased 
level of FABP5 can induce metastasis in vivo [11]. 
Further investigations revealed that metastasis-inducing 
activity of FABP5 was achieved by up-regulating VEGF 
[12]. Thus suppression of FABP5 expression in a highly 
malignant prostate cancer cell line PC3-M significantly 
reduced their invasiveness in vitro [13] and inhibited their 
tumorigenicity in vivo by reducing the level of VEGF 
and microvessel densities. In contrast, increasing FABP5 
expression in the weakly malignant prostate cancer cell 
line LNCaP promoted their invasiveness and proliferation 
rate in vitro and increased their tumorigenicity in vivo [14]. 
Higher levels of both nuclear and cytoplasmic FABP5 in 
prostate carcinoma tissues are significantly associated with 
a reduced patient survival [15]. Recently, it was established 
that cancer promoting activity of FABP5 is closely related 
to its ability to bind and transport extracellular fatty acids 
to their nuclear receptors in prostate cancer cells [14].
Fatty acid receptors termed peroxisome proliferator-
activated receptors (PPARs) belong to the nuclear hormone 
receptor superfamily of ligand-inducible transcription 
factors [16]. All three isotypes (PPARα, PPARβ/δ and 
PPARγ) have been shown to modulate lipid metabolism 
[17]. The important role of PPARs in carcinogenesis was 
highlighted by the ability of their ligands to affect cellular 
proliferation and differentiation or to interfere in apoptosis 
and angiogenesis. While different subtypes of PPARs may 
have effect on tumorigencity of different cancer types, 
high level of expression of PPARγ has been detected in 
prostate cancer and cancers of some other organs [18, 
19]. Although it has been suggested that the increased 
FABP5 may interact with the increased level of PPARγ 
in a coordinated way to facilitate malignant progression 
of prostate cancer cells [20], the exact role of PPARγ 
in tumorigenicity of prostate cancer is not clear. Large 
amount of fatty acids transported by FABP5 can stimulate 
PPARγ [14], but how the activated PPARγ can increase 
the level of VEGF is not known. PPARs can regulate gene 
expression by binding to the PPAR responsive elements 
(PPRE) within the enhancer or promoter sites of the target 
genes. Although VEGF promoter region does contain 
several PPRE sequences, it was not known whether 
PPARγ can promote VEGF expression through binding 
to the PPREs in its promoter region to activate mRNA 
transcription.
In this work, experiments have been performed 
to study the molecular mechanisms of how FABP5 (or 
fatty acids transported by FABP5) transduces signals that 
eventually lead to an involvement in increased VEGF and 
facilitated malignant progression of prostate cancer cells 
in both androgen-dependent and particularly in androgen-
independent subtypes.
RESULTS
Increased PPARγ expression produced by 
FABP5 and establishment of PPARγ-suppressed 
transfectants
To confirm the effect of FABP5 on PPARγ, wild 
type recombinant FABP5 (rFABP5) was used to stimulate 
prostate cancer cells. Western blot analysis (Fig. 1A and 
Fig. 1C) showed that the rFABP5 stimulation produced 
3.15±0.7 fold increase in PPARγ expression in LNCaP 
cells (Fig. 1B) and 2.14±032 fold increase in 22RV1 cells 
(Fig. 1D). To identify the best PPARγ suppresser, PC3-M 
cells were transiently transfected for 24 hours with 3 
candidate double-stranded siRNAs and the changes in 
PPARγ were measured by Western blot (Fig. 1E). When 
the expression level of PPARγ in parental PC3-M cells 
was set at 1.0, the relative levels in cells transfected 
with siRNA 1, 2 and 3 were 0.68 ± 0.15, 0.25 ± 0.11 and 
0.11 ± 0.09, respectively (Fig. 1F), the most significant 
reduction (up to 89%) (Student’s t-test, p < 0.001) was 
achieved by siRNA-3. Thus siRNA-3 was selected as the 
most efficient suppressing sequence to design shRNA for 
stable transfection. The shRNA sequence of siRNA-3 
was cloned into the psiRNA-h7SKGFPzeo plasmid 
and stably transfected into PC3-M cells to knockdown 
PPARγ. Western blots of separate cell lines established 
from individual colonies of transfectants showed a single 
PPARγ band of 57 kDa (Fig. 1G). When the level of 
PPARγ in the parental PC3-M cells was set at 1, the level 
in scrambled RNA control cells was 0.98 ± 0.11 and in 
clones 1-4 was 0.86 ± 0.09, 0.64 ± 0.08, 0.48 ± 0.11 and 
0.18 ± 0.06, respectively (Fig. 1H). Thus levels of PPARγ 
were significantly suppressed by 14-52% (Student’s t-test, 
p = 0.007) in colonies 1-3 and by 82% (Student’s t-test, p 
= 0.0008) in clone 4 cells; there was no significant change 
in scrambled RNA control transfectants. Thus cell lines 
established from clone 3 and clone 4 were selected as 
moderately and highly PPARγ-suppressed transfectants 
and termed PC3-M-PPARγ-si-M and PC3-M-PPARγ-si-H, 
respectively.
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Figure 1: Increased expression of PPARγ by rFABP5 in LNCaP and 22RV1 cells and establishment of colonies 
expressing reduced level of PPARγ by siRNA in PC3-M cells. Quantitative analysis of the levels of PPARγ in different cells was 
performed by densitometry scan of the intensities of the bands of the Western blots. Quantitative results were obtained from 3 repeated blot 
analyses. A. Western blot of PPARγ in untreated LNCaP cells and in cells treated with 50μM rFABP5 at presence of 2μM myristic, palmitic, 
oleic and linoleic acids for 24h. B. Quantitative analysis of PPARγ in control and in rFABP5 treated (at the presence of long chain fatty 
acids) LNCaP cells. The level of PPARγ in untreated control cells was set at 1; and the level in rFABP5 treated cells was obtained by relating 
that to the control. C. Western blot of PPARγ in untreated 22RV1 cells and in cells treated with 50μM rFABP5 at presence of 2μM myristic, 
palmitic, oleic and linoleic acids for 24h. D. Quantitative analysis of PPARγ in control and in rFABP5 treated (at the presence of long chain 
fatty acids) 22RV1 cells. The level of PPARγ in untreated control cells was set at 1; and the level in rFABP5 treated cells was obtained by 
relating that to the control. E. Western blot of PPARγ in parental PC3-M cells, cells treated with transfection reagent (TR) only, or cells 
transfected transiently with scrambled RNA and 3 different siRNA molecules. To standardize the immuno-blot reaction, an anti-β-actin was 
incubated with the same blot. F. Quantitative analysis of the levels of PPARγ in PC3-M cells after transient transfection. The level of PPARγ 
in parental PC3-M was set at 1; Levels in other transfected cells were obtained by comparison with that in PC3-M. G. Western blot analysis 
of the levels of PPARγ in parental PC3-M cells, cells transfected with scrambled shRNA and 4 different clones derived from siRNA-3 stable 
transfectants. An anti-β-actin was incubated with the same blot to normalize possible loading errors. H. Quantitative analysis of the levels 
of PPARγ in parental PC3-M cells, the scrambled shRNA control cells and 4 different clones derived from RNAi-3 stable transfectants. 
The level of PPARγ in parental PC3-M was set at 1; Levels in other transfected cells were obtained by comparison with that in PC3-M.
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Effect of PPARγ suppression on malignant 
properties in vitro and tumorigenicity in vivo
Effects of PPARγ-suppression on proliferation 
rate, anchorage-independent growth and invasiveness of 
prostate cancer cells were evaluated by a proliferation 
assay (Fig. 2A), a soft agar assay (Fig. 2B) and an 
invasion assay (Fig. 2C), respectively. Overall, parental 
cells and control (scrambled) exhibited very similar 
growth patterns when tested with the MTT proliferation 
assay. In the first 48 hours, no significant difference was 
detected amongst all tested cell lines. But from the 3rd day 
onward, cell numbers were significantly reduced in both 
PC3-M-PPARγ-si-H and PC3-M-PPARγ-si-M compared 
Figure 2: Effect of PPARγ suppression on malignant characteristics of PC3-M cells in vitro and their tumourigenicity 
in vivo. A. Effect of PPARγ suppression on proliferation of the transfectant cells over the 5 day experimental period. Results were 
obtained from 3 separate experiments (mean ± SE). B. Effect of PPARγ suppression on anchorage-independent growth of tranfectant cells: 
Representative plates of cell colonies growing in soft agar with different transfectants. C. Effect of PPARγ suppression on invasiveness 
of transfectant cells: Representative Fields of invasion assays are shown. Original magnifications: 100×. D. Average volume of tumors 
produced by each group of nude mice 3 weeks after inoculation with transfectant cells. E. Number of invaded cells per field in invasion 
assay. Results are obtained from three separate measurements (mean ± SE). F. Colony counts of different transfectants growing in soft 
agar after 4 weeks. Results are obtained from three separate plates in the same experiment (mean ± SE). G. A representative mouse and its 
corresponding tumor mass from each group. Presence of tumor cells in all tumor masses has been confirmed by H&E staining (upper figure 
for each tumor). Immunohistochemical staining with PPARγ antibody showed remarkable differences in PPARγ expression between test 
groups and the control (lower figure for each tumor). Original magnifications of slides: 250×.
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to controls. At the end of the 5th day, cell numbers in 
PC3-M and scrambled RNA groups reached 262,000 
± 14,000 and 283,000 ± 9810, respectively; whereas 
in PC3-M-PPARγ-si-H cells and PC3-M-PPARγ-si-M 
cells, they were significantly reduced by 53% and 21% 
to 134,000 ± 19,040 and 224,000 ± 15,200, respectively 
(Student’s t-test, p = 0.009 and p = 0.004). Mean number 
of invaded cells in scrambled (control), PC3-M-PPARγ-
si-M and PC3-M-PPARγ-si-H group was 54 ± 4, 11 ± 2 
and 6 ± 1, respectively (Fig. 2E); representing a significant 
reductions of 79.7% and 88.91%, respectively (Student’s 
t-test, p = 0.0002, p = 0.0003). The number of colonies 
produced in soft agar after 4 weeks by control, PC3-M-
PPARγ-si-M and PC3-M-PPARγ-si-H cells were 756 ± 64, 
80 ± 14 and 45 ± 9, respectively (Fig. 2F), representing 
significant reductions of 89.5% and 94.1%, respectively 
(Student’s t-test, p = 0.0015, p = 0.0012).
To evaluate the effect of PPARγ suppression on 
the tumorigenicity of PC3-M cells in vivo, parental and 
transfectant cells were injected subcutaneously into 
the flanks of nude mice. The median latent period for 
the group with PC3-M-PPARγ-si-H cells was 21 days, 
significantly longer than those with parental cells [6 days 
(range 5-14)] and with PC3-M-PPARγ-si-M cells [11 days 
(range 7-19)]. After three weeks, only 1 of 10 (10%) mice 
with PC3-M-PPARγ-si-H cells produced a visible tumour, 
whereas all mice (100%) with parental cells and 7 out 
of 10 (70%) with PC3-M-PPARγ-si-M cells produced 
tumours (Table 1A). At the end of this experiment, 
average volume of tumours produced by control cells 
(250.6 mm3 ± 60) was significantly larger than those 
produced by PC3-M-PPARγ-si-M cells (19.5 mm3 ± 14.6) 
(Student’s t-test, p = 0.008) and PC3-M-PPARγ-si-H 
cells (2 mm3) (p = 0.0009) (Fig. 2D). At autopsy (three 
weeks after inoculation), average weight of the tumours 
produced by the parental cells was 275 mg ± 105 which 
was significantly higher than those produced by PC3-M-
PPARγ-si-M cells (26.5 mg ± 12.6) (p = 0.002) and PC3-
M-PPARγ-si-H cells (4 mg) (p = 0.0003). Representative 
nude mice from each group, corresponding tumour mass, 
H&E and immunohistochemical staining of tumour tissues 
are shown in Fig. 2G. In control group, 5 (50%) sections 
stained moderately positive and another 5 (50%) sections 
stained strongly positive in the nucleus (Table 1B). 
Among a total of 7 stained sections from PC3-M-PPARγ-
si-M group, 2 (29%) stained weakly and 5 (71%) stained 
moderately positive in the nucleus. Nuclear expression of 
PPARγ in the only tumour produced by PC3-M-PPARγ-
si-H cells was weakly positive. No significant difference 
in cytoplasmic expression of PPARγ in different primary 
tumours was detected. Intensity of staining for PPARγ in 
tumours produced by PC3-M-PPARγ-si-H cells (Fisher 
Exact test, p = 0.002) or PC3-M-PPARγ-si-M cells (p = 
0.02) was significantly weaker compare to those produced 
by parental cells.
FABP5 and PPARγ up-regulated VEGF 
expression
Moderately malignant 22RV1 cells were used 
to study the effect of PPARγ and FABP5 on VEGF 
expression. Quantitative analysis showed that levels of 
FABP5 and PPARγ in PC3-M were respectively 5.4- and 
3.2- fold higher than those in 22RV1 (Fig. 3A, 3B, 3C). 
To test the role of FABP5 on up-regulation of VEGF 
(through PPARγ), 22RV1 cells were treated with PPARγ 
synthetic agonist (rosiglitazone, 0.5 μM) or recombinant 
(r) FABP5 protein (2 μM) overnight. Western blot analysis 
on protein extracts detected two VEGF bands of 19 and 
22kDa (representing VEGF121 and VEGF165 isoforms, 
respectively) in both untreated and treated cells (Fig. 3D). 
When the densitometry measurement level of VEGF in 
untreated 22RV1 cells was set at 1, VEGF levels in cells 
treated with rosiglitazone and rFABP5 were 1.41 ± 0.12 
and 1.36 ± 0.08 (Fig. 3E); significant increment of 41% 
and 36% (Student t-test, p = 0.006), respectively. The 
increment was based on the intensities of both bands. 
Levels of secreted VEGF in conditioned media were 
assessed by ELISA (Fig. 3F). The amount of VEGF 
secreted by 22RV1 cells without any treatment was 120 
± 8.3 pg/ml, while those treated with rosiglitazone (0.5 
μM) or rFABP5 (2 μM) were significantly increased to 
915 ± 37.8 pg/ml (7.6 times; Student t-test, p = 0.0003) 
and 756 ± 25.6 pg/ml (6.3 times; p = 0.0005), respectively. 
Angiogenesis in vitro of secreted VEGF from 22RV1 
cells was evaluated by the ability to stimulate human 
umbilical vein endothelial cells (HUVEC) to form tubes 
(Fig. 3G). The tube-forming ability of HUVEC were 
strongly promoted and well-assembled organizations 
formed in those stimulated with media of rosiglitazone-
treated cells or rFABP5, similar to a positive control with 
10ng/ml recombinant human (rh)VEGF. Conditioned 
medium from the untreated 22RV1 cells caused partially 
visible sprouting of new capillary tubes. The average 
numerical values associated with tube formation showed 
a significant increase in cells treated with rosiglitazone (2-
fold) (Student’s t-test, p = 0.003) or rFABP5 (1.8-fold) ( p 
= 0.006) compared to untreated cells.
To investigate whether FABP5 suppression can down-
regulate VEGF expression through PPARγ, 22RV1 cells 
were treated overnight with PPARγ synthetic antagonist 
(GW9662) (20 μM) and 2 mutant FABP5 recombinant 
proteins (2 μM). These mutant proteins were generated by 
a single mutation (sm) or double mutations (dm) to change 
1 or 2 of the 3 amino acids respectively in the fatty acid-
binding motif of FABP5 [14]. While the fatty acid-binding 
capacity of smrFABP5 is partially lost, dmrFABP5 is 
almost incapable of binding to fatty acids. When the level 
of VEGF in untreated 22RV1 cells was set at 1, levels in 
those treated with GW9662, smrFABP5 and dmrFABP5 
were 0.47 ± 0.08 (Student t-test, p = 0.005), 0.56 ± 0.08 
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( p = 0.007) and 0.49 ± 0.12 ( p = 0.004), respectively (Fig. 
3D, 3E). The amount of VEGF secreted by the cells treated 
with GW9662 (20 μM), smrFABP5 and dmrFABP5 (2 μM) 
were 96 ± 12.1 pg/ml, 102 ± 18.4 pg/ml and 74 ± 6.2 pg/
ml; significant reductions were produced by GW9662 (20%; 
Student’s t-test, p = 0.002), and dmrFABP5 (39%; p = 
0.0009) respectively (Fig. 3F), but not by smrFABP5 (15%, 
p = 0.1). When tested for in vitro angiogenesis by treatment 
with GW9662 or dmrFABP5, HUVEC cells remained 
randomly separated without any sign of a formation of a 
complex mesh; similar to that of the negative control (cells 
treated with normal culture medium) (Fig. 3G). Conditioned 
medium of cells treated with smrFABP5 induced only some 
visible capillary tubes without any sprouting. The average 
numerical values associated with tube formation showed 
a prominent (72%) significant reduction in cells treated 
with GW9662 or dmrFABP5 in comparison to untreated 
22RV1 cells (Student’s t-test, p = 0.01), whereas that for the 
smrFABP5 was not (Student’s t-test, p = 0.11). These results 
suggest that the fatty acid ligands of FABP5 is responsible 
for the increased production of biologically active VEGF in 
22RV1 cells.
To study the possible effect of PPARγ inhibition on 
counteracting up-regulatory effects of FABP5 on VEGF, 
22RV1 cells were treated with PPARγ antagonist GW9662 
(20 μM), rFABP5 (2 μM), or a combination of rFABP5 
with GW9662, overnight. When the level of VEGF in 
untreated 22RV1 cells was set at 1, levels in those treated 
with GW9662, rFABP5 and mixture of rFABP5 with 
GW9662 were 0.47 ± 0.08, 1.36 ± 0.08 and 0.69 ± 0.04, 
respectively (Fig. 3E). Although level of VEGF showed a 
36% increase after treating with rFABP5, a 31% decrease 
was detected after treating with a mixture of rFABP5 and 
GW9662. The VEGF level in GW9662 treated cells is 
significantly lower than that in cells treated by GW9662 
and rFABP5 jointly (Student t-test, p = 0.02). Levels of 
secreted VEGF in conditioned media (Fig. 3F) produced by 
untreated 22RV1 cells, by cells treated with GW9662 (20 
μM), and by rFABP5 alone or a mixture of rFABP5 with 
GW9662 were 120 ± 8.3, 96 ± 12.1, 756 ± 25.6 and 105 
± 9.6 pg/ml, respectively. Although treatment with rFABP5 
alone produced a 6.3-fold increase in secreted VEGF, when 
the rFABP5 was combined with GW9662, the level of 
secreted VEGF was significantly reduced (Student t-test, 
p = 0.0005) to 12.5% below the control. Moreover, the 
average numerical values associated with tube formation 
showed a significant increase (p = 0.006) in the cells treated 
with rFABP5 (1.8-fold); whereas in those cells treated with 
combination of rFABP5 and GW9662, a 42% reduction (Fig. 
3H) was observed, although it was not significantly different 
from their control (Student’s t-test, p = 0.057).
PPARγ regulates VEGF expression through 
acting with PPREs in VEGF promoter
To investigate whether the activated PPARγ (by 
fatty acids transported via FABP5) up-regulated VEGF by 
binding to PPREs in the promoter region of the VEGF 
gene, 22RV1 cells, PC3-M cells, PC3-M-3 cells (FABP5-
suppressed PC3-M cells) and PC3-M-PPARγ-si-H cells 
Table 1: Tumors produced in nude mice and expression of PPARγ in tumor cells
A: Incidence, latent period and average tumor weight




Incidence of  
tumors I
Median of latent 
period (range) II
Average tumor  
weight (mg) III
No. %
PC3-M-PPARγ-si-H 10 1 10 21 4
PC3-M-PPARγ-si-M 10 7 70 11 (7-19) 26.5 ± 12.6
PC3-M (control) 10 10 100 6 (5-14) 275 ± 105
I: Tumor incidence is number of mice developing tumors and percentage is the incidence divided by total number of tested 
mice.
II: Latent period is the number of days from the inoculation time to the time of first appearance of tumor.
III: Tumor weight was measured at autopsy on 21st day after inoculation of the transfectant cells.
B: Nuclear expression of PPARγ in cells of tumors resected from nude mice
Origin of tissue
(mice groups) No. of cases Nuclear staining score (1-9)
≤ 3 4-6 ≥ 9
Control 10 0 5 5
PC3-M-PPARγ-si-M 7 2 5 0
PC3-M-PPARγ-si-H 1 1 0 0
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Figure 3: Up-regulation of VEGF by FABP5 or PPARγ and its biological activity in prostate cancer cells. Significantly 
different results between control and test groups were marked with double asterisks. A. Western blot of FABP5 and PPARγ in androgen-
dependent 22RV1 and androgen-independent PC3-M cells. The anti-β-actin antibody was used to correct possible loading errors in the same 
blot. B. Relative expression of FABP5. C. Relative expression of PPARγ. The levels of both proteins in 22RV1 cells were set as 1.0 and 
levels in PC3-M cells were calculated by relating to those in 22RV1. Results were obtained from three different experiments (mean ± SE). 
From D to H. levels of VEGF produced by androgen-dependent 22RV1 cells and its biological activity after cells were treated overnight 
in different conditions. D. Western blot analysis of VEGF protein in 22RV1cells before and after different treatments (antibody reacts with 
two VEGF splice variants with molecular weights of 19 & 22 kDa). The anti-β-actin was used to correct possible loading errors in the same 
blot. E. Relative levels of VEGF. Level of VEGF in untreated 22RV1 cells was set at 1.0; levels in other cells were calculated by relating 
to that in untreated 22RV1 cells. Results were obtained from three different experiments (mean ± SE). F. ELISA measurement of levels of 
secreted VEGF in 22RV1 conditioned media obtained after different treatments. Results were obtained from three different experiments 
(mean ± SD). G. HUVEC cells’ network formation on ECMatrix, exposed to different 22RV1 conditioned media. Original magnifications 
of representative slides: 250×. The positive control is human rVEGF (10μg/ml) and the negative control is the normal cell culture medium. 
H. Relative values of HUVEC cells’ network formed by addition of different 22RV1 conditioned media. Three individual assays were 
performed for each treatment and the values (mean ± SD) were obtained from five random fields in each assay.
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(PPARγ-suppressed PC3-M cells) were co-transfected 
with following 4 reporter constructs: Control plasmid 
(pGL3-promoter-only), Wild type (WT) which contains 
PPREs, Mutant 1 (M1) which contains the same segment 
of DNA as WT except that both PPREs are mutated, 
and Mutant 2 (M2) which contains a much shorter DNA 
segment without PPREs. All plasmids, the control, WT, 
M1 or M2, contain the luciferase coupled promoters 
of VEGF gene. When the level of luciferase activity in 
22RV1 cells transfected with control plasmid was set as 
1 (Fig. 4A), levels in those transfected with WT, M1 and 
M2 promoters were 2.62 ± 0.26, 2.41 ± 0.25 and 1.29 ± 
0.17, respectively. When the level of luciferase activity in 
PC3-M cells transfected with control plasmid was set as 1, 
levels in those transfected with WT, M1 and M2 promoters 
were 3.3 ± 0.12, 2 ± 0.14 and 1 ± 0.21, respectively. When 
the level of luciferase activity in PC3-M-PPARγ-si-H cells 
transfected with control plasmid was set as 1, levels in 
those transfected with WT, M1 and M2 plasmids were 
2.16 ± 0.22, 1.75 ± 0.24 and 0.99 ± 0.23, respectively. 
When the level of luciferase activity in PC3-M-3 cells 
transfected with control plasmid was set as 1, levels in 
those transfected with WT, M1 and M2 promoters were 
2.5 ± 0.32, 1.71 ± 0.31 and 0.99 ± 0.2, respectively. In this 
set of transfections, only WT and M1 produced significant 
increment in luciferase activity.
To investigate further the effect of PPARγ on 
VEGF-promoter activity, 22RV1 cells were transfected 
with different reporter promoters and treated with 
the PPARγ agonist rosiglitazone (0.5μM). Levels of 
luciferase activity in 22RV1 cells transfected with WT, 
M1 and M2 rose to 4.25 ± 0.35, 2.33 ± 0.50 and 1.42 ± 
0.26, respectively (Fig. 4B). Compared to the untreated 
control, the luciferase activity in cells transfected with WT 
(Student’s t-test, p = 0.0003) and not mutant promoters (p 
≥ 0.25) was significantly higher. After treating with the 
PPARγ antagonist GW9662 (20μM), levels of luciferase 
activity in PC3-M cells transfected with WT, M1 and M2 
were reduced to 2.23 ± 0.12, 1.70 ± 0.22 and 1.15 ± 0.32, 
respectively over the untreated control, which were similar 
to the levels obtained in co-transfected PC3-M-PPARγ-
si-H cells (Fig. 4C). Only that for WT (Student’s t-test, p 
= 0.002) was significantly lower; those for M1 (p = 0.08) 
and M2 (p = 0.27) were not. No significant difference was 
detected between levels of luciferase in transfected PC3-M 
cells treated with GW9662 and that in PC3-M-PPARγ-
si-H cells (p ≥ 0.22).
To study the effect of FABP5 on VEGF-promoter 
activity, cells were treated with rFABP5. Levels of 
luciferase activity in 22RV1 cells co-transfected with 
WT, M1 and M2 were increased to 4.23 ± 0.41, 2.04 ± 
0.32 and 1.26 ± 0.40, respectively. After treating with 
dmrFABP5, luciferase activities in 22RV1 cells transfected 
with WT, M1 and M2 were 2.29 ± 0.35, 2.14 ± 0.32 and 
1.1 ± 0.41, respectively (Fig. 4D). That for WT (Student’s 
t-test, p = 0.004) was significantly higher than the control; 
those for mutant promoters were not (Student’s t-test, p 
= 0.44, p = 0.09). No significant difference was detected 
in luciferase activities between transfected 22RV1 cells 
treated with dmrFABP5 and the cells in the control (p = 
0.33). Comparing with PC3-M cells, the luciferase level in 
PC3-M-3 cells transfected with WT (Student’s t-test, p = 
0.001) was significantly lower; whereas those transfected 
with either M1 or M2 (Student’s t-test, p ≥ 0.07) was not 
significantly different from the control (Fig. 4E).
To study the combined effects of FABP5 and PPARγ 
on VEGF-promoter activity, the luciferase activity of 
22RV1 cells transfected with control plasmid was set as 1, 
the activity of those transfected with WT and treated with 
rosiglitazone (0.5μM), rFABP5 (2μM) and rosiglitazone 
plus rFABP5 were 4.25 ± 0.12, 4.13 ± 0.22 and 4.36 ± 
0.32, respectively. Activity in untreated 22RV1 cells was 
2.62 ± 0.26 (Fig. 4F). The luciferase activities in cells 
transfected with WT and treated with either rosiglitazone 
(Student’s t-test, p = 0.0003), rFABP5 (Student’s t-test, 
p = 0.004) or combination of rosiglitazone and rFABP5 
(Student’s t-test, p = 0.001) were significantly higher in 
comparison to untreated control cells; whereas they were 
not significantly different when compared to each other (p 
= 0.17). When the level of luciferase activity of PC3-M 
cells transfected with control plasmid was set as 1, activity 
in cells transfected with WT was 3.3 ± 0.18. Activities in 
PC3-M cells treated with GW9662 (20μM), untreated 
PC3-M-3 cells and PC3-M-3 cells treated with GW9662 
(20μM) were 2.05 ± 0.24, 2.23 ± 0.21, 1.95 ± 0.19, 
respectively (Fig. 4G), all significantly lower (p ≤ 0.001), 
whereas these levels were not significantly different when 
compared to each other (p ≥ 0.25).
Effects of Sp1 (androgen binding site) on  
VEGF-promoter activity
To study the possible effect of the androgen binding 
site on VEGF-promoter activity, cells were first treated 
with the Sp1 inhibitor mithramycin A (0.1μM) and then 
transfected with different DNA reporter constructs. When 
the luciferase activity in the cells transfected with the 
control was set at 1, luciferase activities in androgen-
sensitive 22RV1 cells transfected with WT, M1 and M2 
were 1.73 ± 0.11, 1.19 ± 0.24 and 0.97 ± 0.31, respectively 
(Fig. 5A). Thus, after treatment with mithramycin A the 
luciferase activity in cells transfected with WT (Student’s 
t-test, p = 0.007) and M1 promoters were significantly 
lower (Student’s t-test p = 0.001) than the untreated 
conrol; but not in cells transfected with M2 (p ≥ 0.1). 
After treating with mithramycin A, luciferase activities in 
androgen-independent PC3-M cells transfected with WT, 
M1 and M2 promoters were 3.2 ± 0.23, 1.7 ± 0.11, 0.95 ± 
0.25, respectively (Fig. 5B), none were significantly lower 
than the untreated control (p ≥ 0.06).
When luciferase activity in 22RV1 cells transfected 
with control plasmid (pGL3-promoter) was set as 1, 
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Figure 4: The effect of PPREs on levels of Luciferase activities in prostate cancer cells transfected with different VEGF 
gene reporter vectors. Following 4 vectors were used to transfect the different prostate cancer cell lines: The control plasmid (pGL3-
promoter-only), WT, M1 and M2. Luciferase activity of the cells transfected with control vector was set at 1; levels in other cells were 
calculated by relating to that of the control. Results were obtained from three different experiments (mean ± SD). Renilla luciferase plasmid 
was co-transfected into cells in every transfection as an internal control to minimize experimental viability caused by possible differences 
of cell viability or transfection efficiency. A. Relative luciferase activities in 22RV1, PC3-M, PC3-M-PPARγ-si-H and PC3-M-3 cells 
transfected with VEGF-promoter-reporter constructs. B. Relative luciferase activities in transfected 22RV1 cells before and after treatment 
with the PPARγ agonist (Rosiglitazone, 0.5μM). C. Relative luciferase activities in transfected PC3-M cells before and after treatment with 
the PPARγ antagonist (GW9662, 20μM) and those in transfected PC3-M-PPARγ-si-H cells without any treatment. D. Relative luciferase 
activities in transfected 22RV1 cells before and after treatment with rFABP5 (2μM) or dmrFABP5 (2μM). E. Relative luciferase activities in 
transfected PC3-M and PC3-M-3 cells without any treatment. F. Relative luciferase activities in 22RV1 transfectant cells (transfected with 
WT or control plasmid) before and after treating with rosiglitazone (0.5μM) and rFABP5 (2μM) either individually or jointly. G. Relative 
luciferase activities in PC3-M and PC3-M-3 transfectant cells before and after GW9662 (20μM) treatment.
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activities in those transfected with WT but without 
any other treatment was 2.62 ± 0.26; activities in those 
cells transfected with WT plasmid and treated with Sp1 
inhibitor mithramycin A (0.1μM), PPARγ antagonist 
GW9662 (20μM) and combination of mithramycin A 
with GW9662 were 1.73 ± 0.11, 2.09 ± 0.12 and 1.28 ± 
0.35, respectively (Fig. 5C). Thus the luciferase activity 
in cells transfected with WT and treated with mithramycin 
Figure 5: The effect of SP1 inhibitor on levels of luciferase activities in prostate cancer cells transfected with different 
VEGF gene reporter vectors. Luciferase activity of the cells transfected with control was set as 1; levels in other cells were calculated 
by relating to that of the control. Results were obtained from three different experiments (mean ± SD). Renilla luciferase plasmid was 
co-transfected into cells in every transfection as an internal control to minimize experimental variability caused by difference of cell 
viability or transfection efficiency. A. Relative luciferase activities in 22RV1 transfectants before and after Sp1 inhibitor (Mithramycin A, 
0.1μM) treatment. B. Relative luciferase activities in PC3-M transfectants before and after Sp1 inhibitor treatment. C. Combined effects 
of Sp1 and PPARγ on VEGF-promoter activity in prostate cancer cells. Relative luciferase activities in 22RV1 transfectants (22RV1 cells 
transfected with control and WT) before and after different treatments; (1) Untreated 22RV1 transfectants, (2) 22RV1 transfectants treated 
with Sp1 inhibitor mithramycin A, (3) 22RV1 transfectants treated with PPARγ antagonist GW9662, (4) 22RV1 transfectants treated with 
both mithramycin A and GW9662.
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A and GW9662 was significantly lower (Students t-test, 
p = 0.026) but not between cells transfected with control 
plasmid and those transfected with WT and treated with 
combinations of mithramycin A and GW9662 ( p = 0.085).
DISCUSSION
Suppression of PPARγ reduced the 
tumorigenicity of prostate cancer cells
When assessing the role of PPARγ in tumorigenicity, 
siRNA knockdown rather than antagonist PPARγ was used 
to avoid any nonspecific effects [21]. When tested in 3 
bioassays that are regarded as important criteria to measure 
tumorigenesis and capability of metastasis of cancer cells 
in in vitro [22], we showed (Fig. 2) that high levels of 
suppression of PPARγ in PC3-M cells (PC3-M-PPARγ-
si-H) produced significant reductions in cell proliferation 
rate, invasiveness, and anchorage-independent growth. 
In nude mouse assay, suppression of PPARγ in PC3-M 
cells significantly reduced the size of tumours by 99%, 
tumour incidence by 90%. When the level of PPARγ was 
moderately suppressed in PC3-M cells, their malignant 
characteristics in vitro and their tumorigenicity in nude 
mice were inhibited, but to a limited degree. Thus the 
malignant characteristics are closely related to the level 
of PPARγ and that PPARγ played an important role in 
tumorigenicity of the prostate cancer cells. Previous 
studies showed that suppression of FABP5 in PC3-M 
cells significantly reduced the same parameters [13, 23]. 
Thus combining current results with those of the past 
suggested that FABP5 and PPARγ may be functioning in a 
coordinated manner to promote the malignant progression 
of human prostate cancer cells.
FABP5 promotes VEGF through PPARγ in 
prostate cancer cells
Increased level of PPARγ in carcinomas can 
stimulate angiogenesis through up-regulation VEGF or 
other pro-angiogenic factors [24-27]. Increased expression 
of FABP5 induced metastasis through up-regulation 
of VEGF [12]; while suppression of FABP5 inhibited 
tumorigenicity by decreasing VEGF expression [23]. 
Here, when 22RV1 cells were treated with rosiglitazone 
and rFABP5, both the cellular and secreted VEGF was 
remarkably increased and which caused great increases in 
angiogenic activity of the conditioned media. Conversely, 
when 22RV1 cells were treated with GW9662 and 
dmrFABP5, VEGF was greatly reduced in both cell 
extracts and conditioned media and the angiogenesis 
activity was greatly reduced. When the fatty acid-binding 
motif in FABP5 was attenuated by mutating 2 of the 3 key 
amino acids, it lost the ability of binding or transporting 
fatty acids [14]. Here when the cells were stimulated 
with dmrFABP5; there was a reduction in the level of 
VEGF and angiogenesis. These results suggest that the 
up-regulation of VEGF was produced by the increased 
cellular uptake of fatty acids transported by FABP5. 
When the ability of binding to and transporting fatty acids 
was lost, dmrFABP5 was not only incapable of inducing 
VEGF, it may also competitively inter-react with the fatty 
acid receptor to prevent FABP5 delivering fatty acids 
to their nuclear receptors and thus cannot initiate the 
down-stream cancer-promoting gene activity. This result 
suggested that dmrFABP5 can act as a suppressor to the 
tumorigenicity-promoting activity of FABP5 and PPARγ.
Like FABP5, PPARγ agonists can promote the up-
regulation of VEGF and increase angiogenesis, whereas 
PPARγ antagonists can reduce VEGF and suppress 
angiogenesis. The suppression of tumorigenicity of 
prostate cancer cells by siRNA knocking down of PPARγ 
was likely to be achieved through inhibiting the biological 
activity of VEGF. In contrast, the result that FABP5 
plus PPARγ antagonists could not induce up-regulation 
of VEGF expression suggested that FABP5 promoted 
VEGF expression and angiogenesis via PPARγ (through 
the stimulation of the fatty acids transported by FABP5). 
When PPARγ was blocked with its antagonists, it did not 
respond to the stimulation signal produced by fatty acids, 
even when high level of fatty acids was available.
PPARγ upregulated VEGF expression acts via 
the PPREs in the VEGF promoter
Although androgen can mediate the upregulation 
of VEGF expression in androgen-dependent prostate 
cancer cells through the Sp1/Sp3 binding site in the 
VEGF core promoter [28], it was not previously known 
how PPARγ exactly up-regulated VEGF in prostate cancer 
cells. Studies showed that the regulatory effect of PPARγ 
ligands on VEGF expression in human endometrial cells 
was modulated through PPREs in the promoter region 
of the VEGF gene [29]. To investigate whether activated 
PPARγ upregulates VEGF and promotes angiogenesis 
in prostate cancer cells in a similar way, a luciferase 
reporter promoter system was employed. Although the 
promoter region of the VEGF gene is relatively long 
and contains many sequences of PPREs, the efficiency 
in promoting the reporter gene expression generated by 
the full length (2274bp) and that produced by a truncated 
(790bp) segment of the VEGF promoter region were very 
similar [29]. Thus in this study, a truncated DNA segment 
containing 2 PPREs, rather than the full-length promoter 
region was used to assess whether PPARγ up-regulates 
VEGF gene through PPREs in the promoter region.
When WT and the control plasmids were co-
transfected into the 22RV1 cells, which expressed low 
levels of PPARγ and FABP5, and treated with the PPARγ 
agonist rosiglitazone, luciferase activity was significantly 
increased from 2.62 to 4.25; whereas in cells transfected 
with other constructs which did not contain PPREs, the 
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luciferase activity was not remarkably changed (Fig. 
4B). Similarly, when the co-transfected highly malignant 
PC3-M cells, which expressed high levels of both PPARγ 
and FABP5, were treated with a PPARγ antagonist 
GW9662, the luciferase activity was remarkably reduced 
to that in M1 transfectants or in PPARγ-suppressed cells 
(PC3-M-PPARγ-si-H) (Fig. 4C).These results showed that 
the increased level of PPARγ and the presence of PPREs 
are essential for VEGF expression in prostate cancer 
cells and suggested that it was the interaction between 
PPARγ and the PPREs in the VEGF promoter region that 
upregulated the VEGF expression.
When the co-transfected 22RV1 cells (with control 
plasmid and WT, M1 and M2, respectively) are treated 
with rFABP5, the level of luciferase activity of the WT 
promoter transfectants is increased by 62%, and no 
increase was observed in either M1 or M2 transfectants 
(Fig. 4D). This result suggests that FABP5 can promote 
VEGF expression only in the presence of PPREs. When 
the same transfectants are treated with the mutant FABP5 
which is incapable of binding fatty acids, no increment 
is observed in any of the 3 transfectants. This result 
suggested that it is the fatty acids transported by FABP5 
that activate PPARγ and upregulate VEGF through 
PPREs. This is further confirmed by the result that when 
expression of FABP5 is knocked down (PC3-M-3 cells), 
the luciferase activity is reduced by 35% compared to the 
co-transfected PC3-M cells (Fig. 4E).
After treating 22RV1 co-transfectants (transfected 
with WT) with PPARγ agonist (rosiglitazone) and 
rFABP5, the luciferase activity was increased by 62% and 
57%, respectively; while subjecting them to a combination 
of both treatments can only raise the luciferase activity 
to a similar level of 66% (Student’s t-test, p ≥ 0.17) (Fig. 
4F). This result suggested that in 22RV1 cells expressing 
low levels of PPARγ and FABP5, both rosiglaitazone 
and rFABP5 can effectively increase VEGF expression 
by the same pathway. In contrast, luciferase activities in 
PC3-M co-transfectants (transfected with WT) treated 
with PPARγ antagonist (GW9662), the untreated PC3-
M-PPARγ-si-H co-transfectants (transfected with WT) 
and PC3-M-3 co-transfectants (transfected with WT) 
are reduced by 32.5%, 35% and 34%, respectively (Fig. 
4G). This result suggests that in PC3-M transfectant cells, 
which expressed high levels of both PPARγ and FABP5, 
suppressing the biological activity of PPARγ by either 
its antagonist or knocking down its mRNA by RNAi (as 
seen in PC3-M-PPARγ-si-H cells) can reduce the level of 
VEGF expression. Furthermore, suppression of FABP5 
expression in PC3-M cells can also reduce the level of 
VEGF (as seen in PC3-M-3). The difference between 
the level of luciferase activity in the untreated FABP5-
knockdown PC3-M-3 cells and that in the cells treated 
with PPARγ antagonist is not significantly (Student’s 
t-test, p = 0.25). This result indicates that when VEGF 
was already reduced by suppressing FABP5, little further 
reduction can be achieved by further treatment with 
PPARγ antagonist. These results taken together confirm 
both FABP5 and PPARγ are involved in an identical 
signalling pathway which regulates VEGF promoter 
activity in prostate cancer cells, as proposed schematically 
in Fig. 6A.
Androgen- and FABP5-PPARγ-pathways 
for modulating VEGF expression and their 
relationship with androgen-dependency of the 
cancer cells
When 22RV1 cells are co-transfected with different 
luciferase constructs, the increase in VEGF expression 
produced by WT was similar to that produced by M1 
which does not contain PPRE. Thus these increases cannot 
have been produced via the PPREs, but rather there are 
some other elements in the promoter region of the VEGF 
which are involved in up-regulating VEGF expression 
in 22RV1 cells. When PC3-M, PC3-M-PPARγ-si-H and 
PC3-M-3 cells were transfected with different constructs, 
both WT and M1 produced increases in luciferase activity. 
This result further confirmed that there are some other 
elements rather than PPREs that can stimulate VEGF 
expression in the highly malignant PC3-M cells (Fig. 4A).
Another possible important mechanism involved is 
the Sp1/Sp3 binding sites and their regulatory effect on 
VEGF activity has been shown in some other cancers, 
such as the up-regulation of VEGF by oestrogen in breast 
cancer cells via the Sp1/Sp3 transcription sites in the core 
VEGF promoter [31]. Similarly, androgen may mediate 
VEGF up-regulation in ADPC cells via Sp1/Sp3 binding 
sites [28]. In this work, after the 22RV1 cells were co-
transfected with WT plus GW9662 and mithramycin A, 
luciferase activity was significantly reduced by 21% and 
34%, respectively (Fig. 5C). These results indicate that in 
androgen responsive 22RV1 cells, both the FABP5-PPARγ 
and the androgen-Sp1 pathways may play important 
roles in up-regulating VEGF expression, although the 
androgen-Sp1 route appeared to be more active than 
the FABP5-PPARγ route. In contrast, when PC3-M co-
transfectants (with WT) are treated with Sp1 inhibitor, 
luciferase activity was hardly reduced (Fig. 5B), whilst 
a significant reduction is achieved by GW9662 (Fig. 4C). 
These results suggest that in castration resistant PC3-M 
cells, the androgen-Sp1 pathway is no longer active in up-
regulating VEGF and the extremely high level of VEGF is 
caused mainly through the FABP5-PPARγ route. This can 
be illustrated in Fig. 6B.
The androgen receptor (AR) plays a key role in 
prostate cancer carcinogenesis [32-34] and prostate 
cancer cells are generally sensitive to the initial androgen 
blockade treatment. But the cancer relapses afterwards 
with a more aggressive form, named castration-resistant 
prostate cancer (CRPC). CRPC does not depend on 
androgen anymore, but continuation of the androgen 
Oncotarget9334www.impactjournals.com/oncotarget
blockade therapy was still widely used to suppress CRPC 
[35, 36]. The molecular pathology involved in how 
androgen-dependent cancer cells are transformed to CRPC 
cells is not fully understood. Currently several mechanisms 
have been hypothesized [20]; the most common one is 
the AR sensitivity amplification theory [37, 38] which 
proposed that when deprived of androgen supply in the 
initial round of therapy, some cells try to maximise their 
Figure 6: Schematic illustrations of how up-regulated VEGF and its biological activity promote tumorigenicity and 
how VEGF is upregulated through 2 different routes in prostate cancer cells. A. Schematic illustration of “FABP5 (fatty 
acids)-PPARγ-VEGF” transduction axis. Through this pathway, fatty acids transported by FABP5 can activate PPARγ which ultimately 
upregulate VEGF. VEGF is a potent antigenic factor which can bind to its receptor VEGFR1 to promote formation of vessel networks 
that are essential for growth and expansion of the cancer cells. VEGF can also promote directly malignancy of the cancer cells through an 
autocrine mechanism to simulate the receptor that is highly expressed on the surface of the prostate cancer cells (VEGFR-2) (Gonzalez-
Moreno et al, 2010). B. Schematic illustration of inter-relationship between androgen-Sp1/Sp3 (sugars) and FABP5 (fatty acids)- PPARγ 
signaling routes in up-regulating VEGF in androgen-dependent and androgen-independent prostate cancer cells. The results in this study 
suggested that in the early stage of prostate cancer, when the cancer cells are still responsive to androgen stimulation, the androgen-Sp1 
pathway plays a dominant role in promoting VEGF expression. As the cancer cells gradually reduce their dependency on androgen supply 
and ultimately lose their responsive to androgen, the role of androgen-Sp1 pathway is gradually reduced and ultimately disappeared in 
AR-negative or androgen independent cancer cells. Opposite to this androgen-Sp1 pathway, the activity of FABP5-PPARγ-VEGF pathway 
in low malignant and androgen dependent cells (with low level of FABP5) is very low. But its activity is increased steadily as the increasing 
level of FABP5 and the malignancy of the cells and becomes dominant in CRPC cells.
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survival ability by increasing the sensitivity of AR to make 
use of the small amount of reduced androgen which has 
escaped from the blockade. Thus some surviving cells 
with an increased ability of using microquantities of 
androgen become dominant and CRPC [39]. Some studies 
also suggested that mutations in AR gene can increase 
sensitivity to androgen [40]. Although each current theory 
can explain certain aspects of this pathological process, 
no single theory can satisfactorily explain all aspects. For 
example, if the AR amplification theory is correct, then 
re-expression of AR in AR-negative and highly malignant 
cells should increase the malignancy, but studies showed 
that the forced re-expression of AR in PC3 actually 
reduced the malignancy of such cells [41].
Based on the results of this and other studies, the 
following alternative hypothesis is proposed to explain the 
molecular mechanism involved in the crucial transition of 
cancer cells from androgen-dependent to an androgen-
independent state: When the cancer cells are deprived of 
androgen supply, most of them die due to starvation, but 
some of them may have survived under the heavy selection 
pressure by switching their reliance on sugar (or glucose) 
uptake (regulated by androgen) [42] to fatty acid uptake 
(transported by FABP5) as an alternative energy source 
(so-called CRPCs). Although these cells can still use 
androgen, and further androgen blockade will kill some 
more cells, it can also make some other cells become even 
more resistant to androgen deprivation and increasing fatty 
acid intake; eventually, completely relying on fatty acids 
as their energy source. The consequence of the increased 
demand of fatty acids and hence the high level of FABP5 
during this process is that the FABP5-PPARγ-VEGF axis 
gradually increases its functional activity and eventually 
replaces the androgen-Sp1/Sp3-VEGF pathway to 
become the dominant route to promote further malignant 
progression. Consequentially, prostate cancer cells will 
ultimately become totally androgen-independent after their 
androgen supply is repeatedly blocked. This can explain 
why androgen blockage can lead to a therapeutic dead end 
[43]. Based on this alternative hypothesis, disrupting the 
FABP5-PPARγ-VEGF signalling axis and cutting off the 
alternative energy supply of the cancer cells, rather than 
blocking the last drop of androgen, should be the correct 
way to kill the AR-negative CRPC cells.
MATERIALS AND METHODS
Cell lines and culture conditions
The following prostate cell lines were used in this 
study: 22RV1 cells, a moderately malignant and androgen-
dependent cell line expressing low levels of FABP5 and 
PPARγ [44]; PC3-M cells, highly malignant and expresses 
very high levels of FABP5 and PPAR [45]; PC3-M-3 
cells, a PC3-M-derived cell line established by knocking 
down FABP5 [15]; PC3-M-PPARγ-si-M and PC3-M-
PPARγ-si-H cells, PC3-M-derived cell lines established 
by knocking down PPARγ gene. Cells were cultured and 
maintained in RPMI 1640 medium (Invitrogen, Paisley, 
UK) supplemented with 10% (v/v) FCS (Biosera, East 
Sussex, UK), penicillin (100 units/ml) and streptomycin 
(100μg/ml) (Invitrogen).
RNA interference
Three pairs of specific PPARγ siRNA sequences, 
chosen by Whitehead siRNA selection program, were 
purchased from Ambion (Life technologies, USA):
Sequence 1, sense strand 5’: GCCCUUCACUAC 
UGUUGACUU; antisence strand 5’: GUCAACAG 
UAGUGAAGGGCUU. Sequence 2, sense strand 5’: 
GGCUUCAUGACAAGGGAGUUU; antisence strand 
5’: ACUCCCUUGUCAUGAAGCCUU. Sequence 3, 
sense strand 5’: UAAAUGUCAGUACUGUCGGUU; 
antisence strand 5’: CCGACAGUACUGACAUUUAUU. 
A scrambled siRNA (Ambion, Inc., USA) was used as 
negative control. PC3-M cells were transfected transiently 
with the X-tremeGENE siRNA Transfection Reagent 
(Roche) and Western blot was performed to measure 
PPARγ level. The siRNA sequence which caused the 
greatest reduction in level of PPARγ was chosen for 
short hairpin RNA (shRNA) construction. Two shRNA 
inserts consisting of PPARγ and scrambled siRNAs were 
designed using siRNA Wizard™ Software (InvivoGen, 
USA) and cloned into the psiRNA-h7SKGFPzeo plasmid 
(InvivoGen, USA) separately. X-tremeGENE HP DNA 
Transfection Reagent (Roche, Germany) was used to 
transfect the PC3-M cells with the vector containing 
PPARγ shRNAs or that harbored scrambled RNA. 
Transfected cells were cultured in a selective medium 
containing Zeocin (100μg/ml) (Life Technologies) for 3-4 
weeks until the cell colonies were visualized. Five single 
colonies were isolated by ring cloning to establish PPARγ-
suppressed sublines. Scrambled RNA transfectants were 
mixed to form a control pool.
Proliferation assay
Transfectant cells were seeded in a 96-well plate 
in triplicate at a density of 1.25×104 cells/200μl medium/
well and colormetrically measured every day for 5 days, 
as described previously [15].
Invasion assay
The BD BioCoat™ Matrigel™ Invasion Chamber 
(BD Biosciences, USA) was used to assess the invasiveness 
of the transfectants, as described previously [14].
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Soft agar assay
Transfectants and PC3-M cells were harvested and 
seeded in 6-well plates with low-melting agarose gel 
(5000 cells/well). After 4 weeks incubation, colonies were 
stained with 0.5 ml MTT (5 mg/ml, Sigma-Aldrich) for 
4 hours. Colonies larger than 150μm were counted using 
an Optronix Gel Count (Oxford Optronix, UK).
Tumorigenicity assay
The tumorigenicity of transfectants was tested by 
inoculating different cells in to male Balb/c 6-8 week old 
nude mice (Charles River Laboratories, UK). Cells (1×106) 
suspended in 200μl PBS were injected subcutaneously 
into the flank of each mouse. Sizes of tumours were 
measured twice a week using callipers. Tumour volumes 
were calculated by the L×W×H×0.5236 formula [46] and 
all tumours were weighed at autopsy (3 weeks after the 
inoculation). The work was conducted under UKCCCR 
guidelines (HO Licence PPL 40/3578).
Immunohistochemical staining
Histological sections (4μm) were cut from 
formalin-fixed, paraffin-embedded primary tumors [47] 
that were removed by dissection, incubated at 37°C 
overnight, deparaffinised with xylene and stained with 
haematoxylin and eosin with an automated Varistain 
24-4 machine (Thermo Scientific, USA). The antibodies 
against FABP5 (Hycult, Netherlands), PPARγ (Santa 
Cruz, USA) and VEGF (Thermo Scientific, USA) 
were purchased commercially and the procedures for 
immunohistochemical staining were similar to those used 
previously [20].
Scoring immunoreactivity
Evaluation of PPARγ immunoreactivity was 
performed in high power fields (×400) using a standard 
light microscope. Nuclear immunoreactivities were 
independently reviewed by two separate observers. 
Nuclear staining was first assessed by the number of 
stained nuclei to obtain a percentage score which was 1 
(≤30%), 2 (31-60%), and 3 (≥61%); then by the intensity 
of staining to obtain an intensity score which was 1 (+), 
2 (++), or 3 (+++). The final score for nuclear staining 
was obtained by multiplying the percentage and intensity 
scores. The final nuclear stains, which scored from 1 to 
9, were further classified into weakly positive (1-3), 
moderately positive (4-6) and strongly positive (7-9), as 
described previously [48].
VEGF ELISA assay
22RV1 cells (1×106 cells/well) were seeded in 
a 6 well plate and cultured in growth factor-deprived 
medium (phenol red-free RPMI 1640 containing 10% 
charcoal stripped FCS) for 48 hours then exposed to 
different treatments overnight. The conditioned medium 
(100μl) of each different treatment was collected and 
transferred to microplate wells where the human VEGF 
level was determined with a VEGF ELISA kit (RayBio) 
following the manufacturer’s instruction. VEGF 
protein concentration in the medium was determined 
colormetrically using a micro-plate reader (BioTek) at 
450 nm.
Angiogenesis assay in vitro
Human umbilical vein endothelial cells (HUVEC) 
were used to evaluate the tube forming ability of 
endothelial cells induced by secreted VEGF in conditioned 
medium. Fifty μl ECMatrixTM Gel (In Vitro Angiogenesis 
Assay Kit, Merck Millipore) were loaded in each well 
of a 96-well plate and the HUVECs (104cells/100μl) 
were seeded on the top of ECMatrix layer in each well. 
Then 100μl of conditioned medium from each different 
treatment was loaded and the plates were incubated at 
37°C, 5% (v/v) CO2 for 6 hours. Recombinant human 
VEGF (10ng/ml) was used as positive control and each 
sample was loaded in triplicate. The cell-tubes were 
visualized by adding 50μl of 2% MTT for 10 minutes at 
room temperature and quantified under an inverted light 
microscope at 40 × magnification.
Dual-luciferase®reporter (DLR™) assay
Three DNA segments based on human VEGF 
promoter sequence [49] (gi|224589818:43727945-
43737944 Homo sapiens chromosome 6, GRCh37.
p10 Primary Assembly) were designed and synthesised. 
Main truncated promoter-region (WT) contained 
5’flanking sequences extending -805 nucleotides from 
the transcriptional start site and including two PPREs 
(-796 to -790bp and -443 to -437bp) [29]. PPRE 
sequence (AGGCCA) [50] in both locations was mutated 
(ATGCAT) in the second DNA fragment. In the third DNA 
fragment, the sequence was shortened to -393bp and both 
PPREs were deleted. These DNA fragments were ligated 
into pGL3 Luciferase Reporter Vectors (Promega, WI, 
USA) to form 3 reporter constructs named WT, M1 and 
M2, respectively. Prostate cancer cell lines were cultured 
and then seeded into 24-well plates (5×104cells/well in 
1ml medium). Cancer cells were transiently co-transfected 
with Renilla luciferase plasmid plus different luciferase 
constructs. The luciferase activities were measured using 
DLR™ Assay (Promega, WI, USA).
Statistical analysis
Student’s t-test was used to evaluate the difference 
in means between two groups for proliferation, invasion, 
in soft agar, in vitro angiogenesis assay, as well as 
Oncotarget9337www.impactjournals.com/oncotarget
average tumour volumes in in vivo assay and difference 
in luciferase levels in DLR assay. A value of p < 0.05 was 
defined as statistically significant. Correlation between 
the PPARγ expression and the sizes of primary tumors 
produced in nude mice was assessed by χ2 analysis.
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